コバヤシ　ヒロヒト   KOBAYASHI Hirohito
  小林　博人
   所属   医学部 医学科（附属足立医療センター）
   職種   准教授
Article types Original article
Language English
Peer review Peer reviewed
Title Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study.
Journal Formal name：Cancer immunology, immunotherapy : CII
Abbreviation：Cancer Immunol Immunother
ISSN code：03407004/03407004
Domestic / ForeginForegin
Volume, Issue, Page 56(4),pp.469-76
Author and coauthor Kobayashi Hirohito, Tanaka Yoshimasa, Yagi Junji, Osaka Yukinari, Nakazawa Hayakazu, Uchiyama Takehiko, Minato Nagahiro, Toma Hiroshi
Authorship Lead author
Publication date 2007/04
Summary PURPOSE:Although various types of immunotherapy have been used to improve the prognosis of patients with advanced renal cell carcinoma (RCC), adoptive immunotherapy using gamma-delta (gammadelta) T cells has not yet been tried. In this study, we designed a pilot study of adoptive immunotherapy using in vitro activated gammadelta T cells against advanced RCC to evaluate the safety profile and possible anti-tumor effects of this study.EXPERIMENTAL DESIGN:Patients with advanced RCC after radical nephrectomy were administered via intravenous infusion in vitro-activated autologous gammadelta T cells every week or every 2 weeks, 6-12 times, with 70 JRU of teceleukin. Adverse events, anti-tumor effects and immunomonitoring were assessed. The anti-tumor effects were evaluated according to tumor doubling time (DT) by computed tomography (CT) and immunomonitoring was performed by flow cytometric analysis.RESULTS:Seven advanced RCC patients were entered in this study. The most common adverse events were fever, general fatigue and elevation of hepatobiliary enzymes, but no severe adverse events were seen. Prolongation of tumor DT was seen in three out of five patients; these three patients showed an increase in the number of gammadelta T cells in peripheral blood and also a high response to the antigen in vitro.CONCLUSIONS:The results indicated that adoptive immunotherapy using in vitro-activated autologous gammadelta T cells was well tolerated and induced anti-tumor effects.
DOI 10.1007/s00262-006-0199-6
PMID 16850345